MPR

LDL-C-Lowering Therapy Lerochol Gains FDA Approval

Lerochol is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
MPR

Varegacestat Improves PFS in Patients With Desmoid Tumors

The pivotal phase 3 RINGSIDE trial investigated varegacestat, an oral gamma secretase inhibitor, in patients with progressing desmoid tumors.
MPR

Enhertu Plus Pertuzumab Approved for First-Line HER2+ Breast Cancer

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).
MPR

Cardamyst Approved for Self-Treatment of PSVT Episodes

Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil.
MPR

Akeega Approved for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
Monthly Prescribing Reference

First-in-Class Oral Antibiotic Nuzolvence Approved for Gonorrhea

Nuzolvence oral granules need to be mixed with water and administered within 15 minutes of mixing. The Food and Drug Administration (FDA) has approved Nuzolvence ® (zoliflodacin for oral suspension) ...